GSK1795091 |
| Catalog No.GC70330 |
GSK1795091 (crx - 601) est un immunostimulant, un agoniste synthétique de TLR4.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1233589-81-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GSK1795091 (CRX-601) ( 0.1 μg /mouse, intranasal administration) as an adjuvant combined with detergent split-influenza antigen (H3N2) induces strong both mucosal and systemic immune responses in mice[2].
GSK1795091 (25 μg/mouse; iv; once weekly for 3 doses) inhibits tumor growth and results in long term survival in tumor model in mice[3].
References:
[1]. Hug BA, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clin Ther. 2020;42(8):1519-1534.e33.
[2]. Maroof A, et.al. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014 Jan;10(1):e1003875.
[3]. Cebada J, et al. OX40 agonists for cancer treatment: a patent review. Expert Opin Ther Pat. 2021 Jan;31(1):81-90.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *